美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Vyome Holdings, Inc.

2.66

-0.1400-5.00%

成交量：10.29萬

成交額：26.77萬

市值：1,501.44萬

市盈率：-0.01

高：2.79

開：2.79

低：2.46

收：2.80

52周最高：305.00

52周最低：1.75

股本：564.45萬

流通股本：309.91萬

量比：2.05

換手率：3.32%

股息：- -

股息率：- -

每股收益(TTM):-183.1419

每股收益(LYR):-0.7646

淨資產收益率：--

總資產收益率：-24.52%

市淨率：5.94

市盈率(LYR):-3.48

資料載入中...

總覽公司新聞資訊公告

Livechain完成對MIT孵化AI人力資源分析公司Humanyze優先擔保債務的收購

Vyome為Vt-1953申請孤兒藥資格認定，未來六個月將深化該項目的戰略佈局

獨立分析師評估：Vyome旗下Vt-1953若三期研究成功，估值將達10億美元

Vyome Holdings, Inc.盤中異動早盤大幅上漲5.97%報2.84美元

Vyome Holdings, Inc.盤中異動早盤急速拉升9.27%報3.30美元

Vyome控股子公司LIVECHAIN INC.收購MIT孵化公司Humanyze的高級擔保票據

Vyome Holdings, Inc.盤中異動下午盤快速下挫6.11%

Vyome Holdings, Inc. - 將與FDA合作設計並啓動2026年重要的三期臨床研究

Vyome公布Vt-1953最終二期試驗積極結果；計劃推進至FDA批准的關鍵研究

Vyome Holdings Inc：VT-1953治療惡性真菌創面的二期研究獲得積極中期數據

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/HIND/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HIND","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIND\",,,,,undefined,":{"symbol":"HIND","market":"US","secType":"STK","nameCN":"Vyome Holdings, Inc.","latestPrice":2.66,"timestamp":1773086400000,"preClose":2.8,"halted":0,"volume":102880,"delay":0,"changeRate":-0.04999999999999989,"floatShares":3099100,"shares":5644494,"eps":-183.1419,"marketStatus":"盤前交易","change":-0.14,"latestTime":"03-10 05:18:21 EDT","open":2.7934,"high":2.7934,"low":2.46,"amount":267714.654928,"amplitude":0.119071,"askPrice":2.98,"askSize":100,"bidPrice":2.5,"bidSize":450,"shortable":0,"etf":0,"ttmEps":-183.1419,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1773149400000},"marketStatusCode":1,"adr":0,"listingDate":1475726400000,"exchange":"NASDAQ","adjPreClose":2.66,"postHourTrading":{"tag":"盘后","latestPrice":2.61,"preClose":2.66,"latestTime":"19:56 EDT","volume":123,"amount":321.8,"timestamp":1773100618775,"change":-0.05,"changeRate":-0.018797,"amplitude":0.018797},"volumeRatio":2.047423653647437},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIND\",,,,,undefined,":{"symbol":"HIND","floatShares":3099100,"roa":"-24.52%","roe":"--","lyrEps":-0.76459,"volumeRatio":2.047423653647437,"shares":5644494,"dividePrice":0,"high":2.7934,"amplitude":0.119071,"preClose":2.8,"low":2.46,"week52Low":1.75,"pbRate":"5.94","psRate":"43.57","week52High":305,"institutionHeld":0,"latestPrice":2.66,"committee":0.636364,"eps":-183.1419,"divideRate":0,"volume":102880,"delay":0,"ttmEps":-183.1419,"open":2.7934,"prevYearClose":3.44,"prevWeekClose":2.8,"prevMonthClose":3.37,"prevQuarterClose":3.44,"fiveDayClose":3.41,"twentyDayClose":2.74,"sixtyDayClose":5.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HIND\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-14","symbol":"HIND","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":-3.12},{"market":"US","date":"2025-08-15","symbol":"HIND","defaultRemindTime":1755264600000,"type":"split","dateTimestamp":1755230400000,"forFactor":4,"toFactor":1,"ratio":4},{"market":"US","date":"2025-08-14","symbol":"HIND","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-2.25},{"market":"US","date":"2025-05-21","symbol":"HIND","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747800000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-05-09","symbol":"HIND","defaultRemindTime":1746797400000,"type":"split","dateTimestamp":1746763200000,"forFactor":25,"toFactor":1,"ratio":25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HIND\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HIND\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1763697600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HIND\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HIND","date":"2026-03-09","current":-0.014524,"percent":0.794118,"low":-23.816091,"twenty":-20.344365,"median":-2.930054,"eighty":-1.672245,"high":-0.001601,"avg":-8.793133,"sd":8.739241,"marketCap":15804583},"quantilePoints":[{"date":"2025-08-22","current":-12.854344,"twenty":-12.392244,"median":-11.699095,"eighty":-11.005946,"marketCap":20748595},{"date":"2025-08-29","current":-11.259279,"twenty":-13.22027,"median":-12.854344,"eighty":-11.500884,"marketCap":18173952},{"date":"2025-09-05","current":-9.124707,"twenty":-13.182739,"median":-11.259279,"eighty":-10.03366,"marketCap":14728473},{"date":"2025-09-12","current":-0.001997,"twenty":-12.854344,"median":-10.288753,"eighty":-0.00213,"marketCap":2910},{"date":"2025-09-19","current":-0.001751,"twenty":-12.467306,"median":-9.124707,"eighty":-0.001933,"marketCap":2551},{"date":"2025-09-26","current":-20.664803,"twenty":-13.499407,"median":-10.288753,"eighty":-0.001997,"marketCap":30109879},{"date":"2025-10-03","current":-20.473816,"twenty":-20.473816,"median":-11.259279,"eighty":-0.002098,"marketCap":29831599},{"date":"2025-10-10","current":-21.00858,"twenty":-21.00858,"median":-13.018541,"eighty":-0.002106,"marketCap":30610783},{"date":"2025-10-17","current":-19.327894,"twenty":-20.855791,"median":-13.499407,"eighty":-0.00213,"marketCap":28161920},{"date":"2025-10-24","current":-20.850495,"twenty":-20.850495,"median":-19.346992,"eighty":-0.002143,"marketCap":30380443},{"date":"2025-10-31","current":-21.039016,"twenty":-20.850495,"median":-19.786263,"eighty":-9.124707,"marketCap":30655130},{"date":"2025-11-07","current":-21.340651,"twenty":-21.039016,"median":-20.206435,"eighty":-10.010203,"marketCap":31094630},{"date":"2025-11-14","current":-18.588235,"twenty":-21.00858,"median":-20.168237,"eighty":-10.03366,"marketCap":27084192},{"date":"2025-11-21","current":-17.984966,"twenty":-21.00858,"median":-20.037322,"eighty":-10.543846,"marketCap":26205192},{"date":"2025-11-28","current":-3.129419,"twenty":-20.886349,"median":-19.767164,"eighty":-7.929274,"marketCap":29238478},{"date":"2025-12-05","current":-3.075047,"twenty":-20.851554,"median":-19.327894,"eighty":-3.104045,"marketCap":28730474},{"date":"2025-12-12","current":-2.881724,"twenty":-20.850495,"median":-18.663643,"eighty":-3.026716,"marketCap":26924236},{"date":"2025-12-19","current":-2.342231,"twenty":-20.820331,"median":-18.362009,"eighty":-2.975968,"marketCap":21883703},{"date":"2025-12-26","current":-2.271547,"twenty":-20.790168,"median":-17.381696,"eighty":-2.665444,"marketCap":21223297},{"date":"2026-01-02","current":-2.078224,"twenty":-20.744922,"median":-13.229653,"eighty":-2.363376,"marketCap":19417059},{"date":"2026-01-09","current":-2.072183,"twenty":-20.685727,"median":-12.660825,"eighty":-2.260673,"marketCap":19360614},{"date":"2026-01-16","current":-1.866777,"twenty":-20.618426,"median":-10.790143,"eighty":-2.104806,"marketCap":17441486},{"date":"2026-01-23","current":-1.761053,"twenty":-20.541319,"median":-10.03366,"eighty":-2.062517,"marketCap":16453700},{"date":"2026-01-30","current":-1.292849,"twenty":-20.511156,"median":-6.2932,"eighty":-1.940481,"marketCap":12079217},{"date":"2026-02-06","current":-1.38951,"twenty":-20.503688,"median":-3.129419,"eighty":-1.87886,"marketCap":12982336},{"date":"2026-02-13","current":-1.576792,"twenty":-20.469996,"median":-3.093171,"eighty":-1.729639,"marketCap":14732129},{"date":"2026-02-20","current":-1.661371,"twenty":-20.454717,"median":-3.029737,"eighty":-1.661371,"marketCap":15522358},{"date":"2026-02-27","current":-2.029893,"twenty":-20.435747,"median":-3.008592,"eighty":-1.661371,"marketCap":18965499},{"date":"2026-03-06","current":-1.758033,"twenty":-20.359224,"median":-2.95875,"eighty":-1.667412,"marketCap":16425477},{"date":"2026-03-09","current":-1.691578,"twenty":-20.344365,"median":-2.930054,"eighty":-1.672245,"marketCap":15804583}],"updateTime":1773132617413},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HIND\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1182593137","title":"Livechain完成對MIT孵化AI人力資源分析公司Humanyze優先擔保債務的收購","url":"https://stock-news.laohu8.com/highlight/detail?id=1182593137","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182593137?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 21:07","pubTimestamp":1771938423,"startTime":"0","endTime":"0","summary":"Livechain已正式完成对Humanyze公司优先担保债务的收购。Humanyze是一家由麻省理工学院孵化、采用人工智能技术的人力资源分析企业。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","LICH","BK4023","BK4082"],"gpt_icon":0},{"id":"1108702394","title":"Vyome為Vt-1953申請孤兒藥資格認定，未來六個月將深化該項目的戰略佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=1108702394","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108702394?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 20:06","pubTimestamp":1770811595,"startTime":"0","endTime":"0","summary":"Vyome Holdings, Inc. 已正式提交Vt-1953的孤儿药资格认定申请，此举标志着公司对该创新药项目的战略重视程度进一步提升。未来六个月内，企业计划集中资源推进Vt-1953项目的研发进程，强化其在特定疾病治疗领域的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","BK4082"],"gpt_icon":0},{"id":"1186890961","title":"獨立分析師評估：Vyome旗下Vt-1953若三期研究成功，估值將達10億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186890961","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186890961?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 21:02","pubTimestamp":1769518963,"startTime":"0","endTime":"0","summary":"据独立分析师最新评估，若Vyome Holdings, Inc.研发的Vt-1953药物能顺利通过三期临床试验，其市场价值有望突破10亿美元大关。这一估值凸显了该创新疗法在医疗领域的巨大潜力，也为投资者提供了明确的价值参考。随着三期研究进入关键阶段，市场对Vt-1953的未来表现持续关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4082","HIND"],"gpt_icon":0},{"id":"2605709334","title":"Vyome Holdings, Inc.盤中異動 早盤大幅上漲5.97%報2.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605709334","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605709334?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 23:27","pubTimestamp":1769095657,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日23时27分，Vyome Holdings, Inc.股票出现波动，股价大幅上涨5.97%。截至发稿，该股报2.84美元/股，成交量6434股，换手率0.11%，振幅4.85%。Vyome Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.82%。其相关个股中，60 Degrees Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Io Biotech, Inc.涨幅较大，60 Degrees Pharmaceuticals, Inc.、Oragenics Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为11727.51%、370.41%、288.13%，振幅较大的相关个股有60 Degrees Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为131.00%、69.40%、36.70%。Vyome Holdings, Inc.公司简介：Vyome Holdings Inc是一家研发公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012223273897a2fc55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012223273897a2fc55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","BK4007","HIND"],"gpt_icon":0},{"id":"2603951817","title":"Vyome Holdings, Inc.盤中異動 早盤急速拉升9.27%報3.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603951817","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603951817?lang=zh_tw&edition=fundamental","pubTime":"2026-01-15 22:33","pubTimestamp":1768487619,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日22时33分，Vyome Holdings, Inc.股票出现波动，股价急速上涨9.27%。截至发稿，该股报3.30美元/股，成交量629股，换手率0.01%，振幅6.62%。Vyome Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。其相关个股中，Cns Pharmaceuticals, Inc.、Ocular Therapeutix, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 涨幅较大，Gt Biopharma, Inc.、Applied Therapeutics, Inc.、Genprex, Inc.较为活跃，换手率分别为48.80%、42.49%、15.18%，振幅较大的相关个股有Cns Pharmaceuticals, Inc.、Metavia Inc.、60 Degrees Pharmaceuticals, Inc.，振幅分别为15.65%、12.18%、11.84%。Vyome Holdings, Inc.公司简介：Vyome Holdings Inc是一家研发公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115223339a4c81a8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115223339a4c81a8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4082","HIND"],"gpt_icon":0},{"id":"1137069214","title":"Vyome控股子公司LIVECHAIN INC.收購MIT孵化公司Humanyze的高級擔保票據","url":"https://stock-news.laohu8.com/highlight/detail?id=1137069214","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137069214?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 21:03","pubTimestamp":1766408623,"startTime":"0","endTime":"0","summary":"Vyome控股子公司LIVECHAIN INC.将收购MIT孵化公司Humanyze的高级担保票据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4082","BK4007","LICH","HIND"],"gpt_icon":0},{"id":"2592197015","title":"Vyome Holdings, Inc.盤中異動 下午盤快速下挫6.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592197015","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592197015?lang=zh_tw&edition=fundamental","pubTime":"2025-12-20 03:38","pubTimestamp":1766173114,"startTime":"0","endTime":"0","summary":"北京时间2025年12月20日03时38分，Vyome Holdings, Inc.股票出现波动，股价快速跳水6.11%。截至发稿，该股报3.64美元/股，成交量1.9053万股，换手率0.34%，振幅8.19%。Vyome Holdings, Inc.股票所在的生物技术行业中，整体涨幅为1.47%。其相关个股中，Novabay Pharmaceuticals, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、爱美医疗涨幅较大，Psyence Biomedical Ltd.、In8Bio, Inc.、Neuraxis, Inc.较为活跃，换手率分别为1793.90%、224.50%、137.82%，振幅较大的相关个股有Novabay Pharmaceuticals, Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Geovax Labs, Inc.，振幅分别为92.37%、59.87%、57.35%。Vyome Holdings, Inc.公司简介：Vyome Holdings Inc是一家研发公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220033835953b7696&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220033835953b7696&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HIND","BK4082","BK4007"],"gpt_icon":0},{"id":"1116502243","title":"Vyome Holdings, Inc. - 將與FDA合作設計並啓動2026年重要的三期臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1116502243","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116502243?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:13","pubTimestamp":1765199623,"startTime":"0","endTime":"0","summary":"Vyome Holdings, Inc. - 将与FDA合作设计并启动2026年重要的三期临床研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4007","BK4082"],"gpt_icon":0},{"id":"1170919255","title":"Vyome公布Vt-1953最終二期試驗積極結果；計劃推進至FDA批准的關鍵研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1170919255","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170919255?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:12","pubTimestamp":1765199558,"startTime":"0","endTime":"0","summary":"Vyome公布Vt-1953最终二期试验积极结果；计划推进至FDA批准的关键研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4007","HIND"],"gpt_icon":0},{"id":"1175842988","title":"Vyome Holdings Inc：VT-1953治療惡性真菌創面的二期研究獲得積極中期數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1175842988","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175842988?lang=zh_tw&edition=fundamental","pubTime":"2025-09-04 20:32","pubTimestamp":1756989144,"startTime":"0","endTime":"0","summary":"Vyome Holdings Inc：VT-1953治疗恶性真菌创面的二期研究获得积极中期数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIND","BK4082"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}